Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07100080 · ClinicalTrials.gov registry record · Phase 2

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 2
Development phase
596
Enrollment target
20
Study locations

NCT07100080 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 596 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07100080, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 2
Development phase
596 participants
Enrollment target
20
Study locations

Study Summary

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • DRUG Iza-bren

Study Locations (20)

New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island - Mineola
  • NYU Langone Health - New York
  • Local Institution - 0158 - New York
  • Local Institution - 0186 - Rochester

Oregon

  • Local Institution - 0038 - Portland
  • Local Institution - 0275 - Portland
  • Local Institution - 0171 - Portland

California

  • Local Institution - 0279 - Irvine
  • Local Institution - 0154 - Orange

Florida

  • Local Institution - 0085 - Gainesville
  • Local Institution - 0142 - Pembroke Pines

Georgia

  • Local Institution - 0270 - Atlanta
  • Local Institution - 0143 - Columbus

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland
  • Local Institution - 0284 - Columbus

Colorado

  • Shaw Cancer Center - Edwards

Illinois

  • Local Institution - 0153 - Chicago

Trial Details

FieldValue
Enrollment Target 596 participants
Start Date 2025-11-05
Est. Completion 2031-05-15
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07100080

The ClinicalTrials.gov registry entry for NCT07100080 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT07100080 reports 20 study locations spanning 11 distinct geographic areas - top geographies include New York, Oregon, California.

Frequently Asked Questions

What is clinical trial NCT07100080 about?

NCT07100080 is a clinical study titled "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)". A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

What is the current status of trial NCT07100080?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 596 participants. The study started on 2025-11-05. Estimated completion is 2031-05-15.

What conditions does trial NCT07100080 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT07100080?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Iza-bren (DRUG).

Who is sponsoring clinical trial NCT07100080?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07100080 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.